Available datapackage for study 'A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE'
收藏DataCite Commons2025-10-29 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00009495.0
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this phase 3 study is to investigate the efficacy and safety, including
immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics
(PK), health related quality of life (HRQoL) and pharmacoeconomics of prophylactic treatment
with recombinant von Willebrand factor (rVWF) (vonicog alfa) in adult participants with
severe von Willebrand disease (VWD).
提供机构：
Vivli
创建时间：
2025-10-29
